Intravascular Imaging Incorporated

i3 is a pioneering company specializing in advanced cardiovascular imaging technologies aimed at the early detection and post-interventional viability of coronary artery disease. Collaborating with prestigious institutions like Massachusetts General Hospital, Harvard Medical School, and the Technical University of Munich, i3 leverages cutting-edge biological imaging modalities to provide clinicians with comprehensive insights during PCI (Percutaneous Coronary Intervention) procedures. The company's flagship product, the I3 NIRF IVUS catheter, combines traditional intravascular ultrasound with biological information to visualize pathophysiological data, offering a more detailed view of the vessel's condition.

Operating in the medical imaging market, i3 primarily serves healthcare providers and clinicians specializing in cardiovascular treatments. The business model revolves around the commercialization of its proprietary imaging technologies, generating revenue through the sale of its advanced catheters and related imaging systems. By improving the accuracy and effectiveness of coronary artery disease treatments, i3 aims to reduce the rates of in-stent restenosis, potentially saving billions in unnecessary medical expenses globally.

Keywords: cardiovascular imaging, early detection, coronary artery disease, PCI procedures, biological imaging, intravascular ultrasound, pathophysiological data, healthcare providers, medical imaging market, in-stent restenosis.